Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Roche & Zealand Pharma join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. See why this ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

The agreement covering the compound petrelintide, announced by Roche on Wednesday, marks renewed efforts to catch up with weight-loss market leaders Novo Nordisk and Eli Lilly .

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

Shares of Danish obesity-drug maker Novo Nordisk, which provided clinical trial data from its CagriSema product that disappointed investors on Monday, continued their retreat, and are down about 11% ...

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...